Hybrid models combining methylation with somatic mutations (e.g., KRAS, TP53), proteomic biomarkers (e.g., CA-125, CEA), or transcriptomic signatures could enhance diagnostic, classification accuracy and provide a more comprehensive view of tumor biology. The gene discussed is TP53; the disease is neoplasm.